ArticleJournal of neuro-oncology2025
Incidence of rare malignant transformation in vestibular schwannomas treated with stereotactic radiosurgery: a single-institution analysis of 1,061 cases.
Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Birds on a wire: Gamma Knife radiosurgery for two schwannomas along the same cranial nerve. Illustrative case.Journal of neurosurgery. Case lessons · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study assesses the incidence of malignant transformation (MT) in vestibular schwannomas (VSs) treated with stereotactic radiosurgery (SRS) over a 30-year period, with a median follow-up of 12 years.
methodsA retrospective analysis was performed on 1,051 individuals who underwent gamma knife surgery (GKS) for VS between May 1991 and March 2023. The cohort comprised 1,013 individuals with sporadic VSs and 38 with neurofibromatosis type 2-related schwannomatosis (NF2-SWN), totaling 1,061 treated VSs. The annual MT risk was calculated based on lesion-years at risk.
resultsAmong the 1,061 VSs treated with GKS, MT occurred in 2 cases (0.19%), both in individuals with sporadic VSs. Over 12,940 lesion-years from GKS to the latest follow-up, the annual MT risk was 0.016% for all VSs, with no cases observed within the first 5 years post-GKS. However, the risk increased to 0.025% beyond 5 years. No instances of MT were identified in individuals with NF2-SWN.
conclusionsThis study represents the most extensive investigation specifically examining the incidence of MT in VSs treated with SRS, leveraging the largest case series and longest observation period to date. The findings indicate that MT following SRS for VSs is exceedingly rare. Although the overall risk remains minimal, it may increase slightly with extended follow-up. These results support the continued use of SRS as a safe and effective treatment for VS while emphasizing the need for long-term monitoring.
Indexed as
Identifiers
40202568What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.